Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 11 people enrolled
- Started
- 17 Jul 2018
- Ended
- 20 Mar 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- TTRNA-DC vaccines with GM-CSF
- TTRNA-xALT
- Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
- Dose-Intensified TMZ
- Td vaccine
- Autologous Hematopoietic Stem Cells (HSC)
- Record updated
- 29 October 2025
- Why it stopped
- Not feasible to accrue due to competing studies
Who can take part
- Age
- 3 years to 30 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (30)Hide the full registry criteria
Who can take part
- Initial Screening
- Radiologically confirmed DIPG or other diffuse intrinsic brain stem glioma (Grade III or IV)
- Patient and/or parents/guardian willing to consent to biopsy for obtaining tumor material for confirmatory diagnosis and/or tumor RNA extraction and amplification
- Biopsy confirmation of any grade of glioma (for patients with classic DIPG on neuroimaging or at least grade III glioma in case of other diffuse intrinsic brain stem gliomas)
- Karnofsky Performance Status (KPS) of > 50% (KPS for > 16 years of age) or Lansky performance Score (LPS) of ≥ 50 (LPS for ≤ 16 years of age) assessed within 2 weeks prior to registration
- Bone Marrow
- ANC (absolute neutrophil count) ≥ 1000/µl (unsupported)
- Platelets ≥ 100,000/µl (unsupported)
- Hemoglobin > 8 g/dL (can be transfused)
- Renal
- Serum creatinine ≤ upper limit of institutional normal
- Hepatic
- Bilirubin ≤ 1.5 times upper limit of institutional normal for age
- SGPT (ALT) ≤ 3 times upper limit of institutional normal for age
- SGOT (AST) ≤ 3 times upper limit of institutional normal for age
- Patients of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control while being treated on this study
- Signed informed consent according to institutional guidelines; Post Biopsy
- Patients with post-surgical neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
- Pathologic diagnosis of glioma on tumor biopsy
Who cannot take part
- Severe or unstable concurrent medical conditions
- Patients who require corticosteroids above physiologic doses (>4 mg/day dexamethasone) after chemoradiotherapy
- Patients scheduled to receive any other concurrent anticancer or investigational drug therapy
- Prior allergic reaction to TMZ, GM-CSF, or Td
- Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection
- Patients with significant renal, cardiac, pulmonary, hepatic or other organ dysfunction
- Pregnant or need to breast feed during the study period (Negative serum pregnancy test required)
- Patients with severe dysphagia, obtundation, or tetraplegia (poor risks for anesthesia and biopsy procedure)
- Absence of tumor on biopsy specimen
- Patients who are unwilling or unable to receive treatment and undergo follow-up evaluations at University of Florida
- Patient and/or parent/guardian demonstrating an inability to comply with the study and/or follow-up procedures
Where in United States
- UF Health Shands Children's HospitalGainesville, United States
About the trial
What the trial wants to find out
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment. The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective. Recent studies in adults have shown that certain types of chemotherapy induce a profound but transient lymphopenia (low blood lymphocytes) and vaccinating and/or the adoptive transfer of tumor-specific lymphocytes into the cancer patient during this lymphopenic state leads to dramatic T cell expansion and potent immunologic and clinical responses. Therefore, patients in this study will either receive concurrent TMZ during RT and immunotherapy during and after maintenance cycles of dose-intensive TMZ (Group A) or focal radiotherapy alone and immunotherapy without maintenance DI TMZ (Group B). Immune responses during cycles of DC vaccination with or without DI TMZ will be evaluated in both treatment groups.
The 2 groups in the trial
- Group ATreatment being tested
TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) during cycles of Dose-intensified TMZ
Treatment: TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Dose-Intensified TMZ, Td vaccine, and Autologous Hematopoietic Stem Cells (HSC)
- Group BTreatment being tested
TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) with Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
Treatment: TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Td vaccine, and Autologous Hematopoietic Stem Cells (HSC)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Recovery From Focal Radiotherapy Alone or Focal Radiotherapy and Dose-intensified Temozolomide (Phase I)
- Record updated
- 29 October 2025